Treatment of Ulcerative Colitis by Cationic Liposome Delivered NLRP3 siRNA

References

• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi:10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Bateman RM, Sharpe MD, Jagger JE, et al. 36th international symposium on intensive care and emergency medicine: Brussels, Belgium. 15–18 March 2016. Crit Care. 2016;20(Suppl 2):94. doi:10.1186/s13054-016-1208-6
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913. doi:10.1053/j.gastro.2008.09.012
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519–525. doi:10.1007/s10620-012-2371-5
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62(4):630–649. doi:10.1136/gutjnl-2012-303661
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794–4801. doi:10.3748/wjg.v22.i20.4794
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755. doi:10.1016/S0140-6736(16)31711-1
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–1605. doi:10.1016/S0140-6736(12)60026-9
   PubMed Web of Science ®Google Scholar
• Alfagih IM, Aldosari BN, AlQuadeib BT, et al. An overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis. Curr Pharm Des. 2021;27(25):2904–2914. doi:10.2174/1381612827666210617120302
   PubMed Web of Science ®Google Scholar
• Lv Q, Xing Y, Liu J, et al. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation. Acta Pharm Sin B. 2021;11(9):2880–2899. doi:10.1016/j.apsb.2021.03.011
   PubMed Web of Science ®Google Scholar
• Shen -H-H, Yang Y-X, Meng X, et al. NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev. 2018;17(7):694–702. doi:10.1016/j.autrev.2018.01.020
   PubMed Web of Science ®Google Scholar
• Sharma BR, Kanneganti T-D. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22(5):550–559. doi:10.1038/s41590-021-00886-5
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328
   PubMed Web of Science ®Google Scholar
• Sharif H, Wang L, Wang WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature. 2019;570(7761):338–343. doi:10.1038/s41586-019-1295-z
   PubMed Web of Science ®Google Scholar
• Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114–2127. doi:10.1038/s41423-021-00740-6
   PubMed Web of Science ®Google Scholar
• Zhen Y, Zhang H. NLRP3 inflammasome and inflammatory bowel disease. Front Immunol. 2019;10:276. doi:10.3389/fimmu.2019.00276
   PubMed Web of Science ®Google Scholar
• Coccia M, Harrison OJ, Schiering C, et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J Exp Med. 2012;209(9):1595–1609. doi:10.1084/jem.20111453
   PubMed Web of Science ®Google Scholar
• Lazaridis L-D, Pistiki A, Giamarellos-Bourboulis EJ, et al. Activation of NLRP3 inflammasome in inflammatory bowel disease: differences between Crohn’s Disease and ulcerative colitis. Dig Dis Sci. 2017;62(9):2348–2356. doi:10.1007/s10620-017-4609-8
   PubMed Web of Science ®Google Scholar
• Cao R, Ma Y, Li S, et al. 1,25(OH)(2) D(3) alleviates DSS-induced ulcerative colitis via inhibiting NLRP3 inflammasome activation. J Leukoc Biol. 2020;108:283–295. doi:10.1002/JLB.3MA0320-406RR
   PubMed Web of Science ®Google Scholar
• Zhang H-X, Wang Z-T, Lu -X-X, et al. NLRP3 gene is associated with ulcerative colitis (UC), but not Crohn’s disease (CD), in Chinese Han population. Inflamm Res. 2014;63(12):979–985. doi:10.1007/s00011-014-0774-9
   PubMed Web of Science ®Google Scholar
• Hanaei S, Sadr M, Rezaei A, et al. Association of NLRP3 single nucleotide polymorphisms with ulcerative colitis: a case-control study. Clin Res Hepatol Gastroenterol. 2018;42(3):269–275. doi:10.1016/j.clinre.2017.09.003
   PubMed Web of Science ®Google Scholar
• Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59(9):1192–1199. doi:10.1136/gut.2009.197822
   PubMed Web of Science ®Google Scholar
• Du X, Chen W, Wang Y, et al. Therapeutic efficacy of carboxyamidotriazole on 2,4,6-trinitrobenzene sulfonic acid-induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF-kappaB activation. Int Immunopharmacol. 2017;45:16–25. doi:10.1016/j.intimp.2017.01.015
   PubMed Web of Science ®Google Scholar
• Zhou W, Liu X, Zhang X, et al. Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome. Oncotarget. 2017;8(35):58903–58917. doi:10.18632/oncotarget.19440
   PubMedGoogle Scholar
• Bauer C, Duewell P, Lehr H-A, et al. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis. 2012;30(Suppl 1):82–90. doi:10.1159/000341681
   PubMedGoogle Scholar
• Burri E, Maillard MH, Schoepfer AM, et al. Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update. Digestion. 2020;101(Suppl 1):2–15. doi:10.1159/000504092
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence. 2010;1(1):14. doi:10.1186/1758-907X-1-14
   PubMedGoogle Scholar
• Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133–147. doi:10.1016/j.addr.2019.05.004
   PubMed Web of Science ®Google Scholar
• Kim B, Park J-H, Sailor MJ. Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery. Adv Mater. 2019;31(49):e1903637. doi:10.1002/adma.201903637
   PubMed Web of Science ®Google Scholar
• Saw PE, Song E-W. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63(4):485–500. doi:10.1007/s11427-018-9438-y
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. doi:10.1038/s41392-020-0207-x
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi:10.1056/NEJMoa1716153
   PubMed Web of Science ®Google Scholar
• Lee K, Jang B, Lee Y-R, et al. The cutting-edge technologies of siRNA delivery and their application in clinical trials. Arch Pharm Res. 2018;41(9):867–874. doi:10.1007/s12272-018-1069-4
   PubMed Web of Science ®Google Scholar
• Hu B, Weng Y, Xia X-H, et al. Clinical advances of siRNA therapeutics. J Gene Med. 2019;21(7):e3097. doi:10.1002/jgm.3097
   PubMed Web of Science ®Google Scholar
• Zhang H, Men K, Pan C, et al. Treatment of colon cancer by degradable rrPPC nano-conjugates delivered STAT3 siRNA. Int J Nanomedicine. 2020;15:9875–9890. doi:10.2147/IJN.S277845
   PubMed Web of Science ®Google Scholar
• Song P, Yang C, Thomsen JS, et al. Lipidoid-siRNA nanoparticle-mediated IL-1β gene silencing for systemic arthritis therapy in a mouse model. Mol Ther. 2019;27(8):1424–1435. doi:10.1016/j.ymthe.2019.05.002
   PubMed Web of Science ®Google Scholar
• Duan W, Li H. Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis. J Nanobiotechnology. 2018;16(1):58. doi:10.1186/s12951-018-0382-x
   PubMedGoogle Scholar
• Luo X, Wang W, Dorkin JR, et al. Poly(glycoamidoamine) brush nanomaterials for systemic siRNA delivery in vivo. Biomater Sci. 2017;5(1):38–40. doi:10.1039/c6bm00683c
   Web of Science ®Google Scholar
• Yang C, Merlin D. Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. Int J Nanomedicine. 2019;14:8875–8889. doi:10.2147/IJN.S210315
   PubMed Web of Science ®Google Scholar
• Scherman D, Rousseau A, Bigey P, et al. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications. Gene Ther. 2017;24(3):151–156. doi:10.1038/gt.2017.6
   PubMed Web of Science ®Google Scholar
• Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(2):274–283. doi:10.1080/21691401.2017.1307210
   PubMed Web of Science ®Google Scholar
• Patil P, Gao YG, Lin L, et al. The development of functional non-viral vectors for gene delivery. Int J Mol Sci. 2019;20(21):5491. doi:10.3390/ijms20215491
   PubMed Web of Science ®Google Scholar
• Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2(3):624–641. doi:10.3390/vaccines2030624
   PubMedGoogle Scholar
• Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321–340. doi:10.1016/j.biomaterials.2016.06.018
   PubMed Web of Science ®Google Scholar
• Brooks PJ, Yang NN, Austin CP. Gene therapy: the view from NCATS. Hum Gene Ther. 2016;27(1):7–13. doi:10.1089/hum.2016.29018.pjb
   PubMed Web of Science ®Google Scholar
• Zheng Q, Lin D, Lei L, et al. Engineered non-viral gene vectors for combination cancer therapy: a review. J Biomed Nanotechnol. 2017;13(12):1565–1580. doi:10.1166/jbn.2017.2489
   PubMed Web of Science ®Google Scholar
• Wu P, Chen H, Jin R, et al. Non-viral gene delivery systems for tissue repair and regeneration. J Transl Med. 2018;16(1):29. doi:10.1186/s12967-018-1402-1
   PubMedGoogle Scholar
• Bhattacharya S, Bajaj A. Fluorescence and thermotropic studies of the interactions of PEI-cholesterol based PEI-chol lipopolymers with dipalmitoyl phosphatidylcholine membranes. Biochim Biophys Acta. 2008;1778(10):2225–2233. doi:10.1016/j.bbamem.2008.05.005
   PubMed Web of Science ®Google Scholar
• Gao C, Yu S, Zhang X, et al. Dual functional Eudragit® S100/L30D-55 and PLGA colon-targeted nanoparticles of iridoid glycoside for improved treatment of induced ulcerative colitis. Int J Nanomedicine. 2021;16:1405–1422. doi:10.2147/IJN.S291090
   PubMed Web of Science ®Google Scholar
• Ren G, Zhang X, Xiao Y, et al. ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination. EMBO J. 2019;38(6). doi:10.15252/embj.2018100376
   Web of Science ®Google Scholar
• Zhang J, Cui -W-W, Du C, et al. Knockout of DNase1l1l abrogates lens denucleation process and causes cataract in zebrafish. Biochim Biophys Acta Mol Basis Dis. 2020;1866(5):165724. doi:10.1016/j.bbadis.2020.165724
   PubMed Web of Science ®Google Scholar
• Zhu S, Zeng M, Feng G, et al. Platinum nanoparticles as a therapeutic agent against dextran sodium sulfate-induced colitis in mice. Int J Nanomedicine. 2019;14:8361–8378. doi:10.2147/IJN.S210655
   PubMed Web of Science ®Google Scholar
• Zhang H, Ma Y, Cao R, et al. Soluble uric acid induces myocardial damage through activating the NLRP3 inflammasome. J Cell Mol Med. 2020;24(15):8849–8861. doi:10.1111/jcmm.15523
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen X, Zong B, et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. J Cell Mol Med. 2018;22:4437–4448. doi:10.1111/jcmm.13743
   PubMed Web of Science ®Google Scholar
• Paik S, Kim JK, Silwal P, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18(5):1141–1160. doi:10.1038/s41423-021-00670-3
   PubMed Web of Science ®Google Scholar
• Schwaid AG, Spencer KB. Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. J Med Chem. 2021;64(1):101–122. doi:10.1021/acs.jmedchem.0c01307
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Koletzko S, Kannengiesser K, et al. Ulcerative colitis-diagnostic and therapeutic algorithms. Dtsch Arztebl Int. 2020;117(33–34):564–574. doi:10.3238/arztebl.2020.0564
   PubMed Web of Science ®Google Scholar
• Kato S, Ishibashi A, Kani K, et al. Optimized management of ulcerative proctitis: when and how to use mesalazine suppository. Digestion. 2018;97(1):59–63. doi:10.1159/000484224
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. doi:10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Parihar V, Maguire S, Shahin A, et al. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone. Ir J Med Sci. 2016;185(4):965–967. doi:10.1007/s11845-015-1355-9
   PubMed Web of Science ®Google Scholar
• Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther. 2005;22(10):907–916. doi:10.1111/j.1365-2036.2005.02680.x
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Osterman MT. Biologic therapy for ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):717–729. doi:10.1016/j.gtc.2020.08.002
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421–446. doi:10.1038/s41573-019-0017-4
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138. doi:10.1038/nrd2742
   PubMed Web of Science ®Google Scholar
• Weng Y, Huang Q, Li C, et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol Ther Nucleic Acids. 2020;19:581–601. doi:10.1016/j.omtn.2019.12.004
   PubMedGoogle Scholar
• Shang S, Monfregola L, Caruthers MH. Peptide-substituted oligonucleotide synthesis and non-toxic, passive cell delivery. Signal Transduct Target Ther. 2016;1(1):16019. doi:10.1038/sigtrans.2016.19
   PubMedGoogle Scholar
• Oliveira C, Ribeiro AJ, Veiga F, et al. Recent advances in nucleic acid-based delivery: from bench to clinical trials in genetic diseases. J Biomed Nanotechnol. 2016;12(5):841–862. doi:10.1166/jbn.2016.2245
   PubMed Web of Science ®Google Scholar
• Charbe NB, Amnerkar ND, Ramesh B, et al. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B. 2020;10:2075–2109. doi:10.1016/j.apsb.2020.10.005
   PubMed Web of Science ®Google Scholar
• Titze-de-Almeida R, David C, Titze-de-Almeida SS. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017;34(7):1339–1363. doi:10.1007/s11095-017-2134-2
   PubMed Web of Science ®Google Scholar
• Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009;458(7242):1180–1184. doi:10.1038/nature07774
   PubMed Web of Science ®Google Scholar
• Laroui H, Viennois E, Xiao B, et al. Fab’-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release. 2014;186:41–53. doi:10.1016/j.jconrel.2014.04.046
   PubMed Web of Science ®Google Scholar
• Huang Y, Guo J, Gui S. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-a siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. Eur J Pharm Sci. 2018;125:232–243. doi:10.1016/j.ejps.2018.10.009
   PubMed Web of Science ®Google Scholar
• Tong L, Hao H, Zhang Z, et al. Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota. Theranostics. 2021;11(17):8570–8586. doi:10.7150/thno.62046
   PubMed Web of Science ®Google Scholar
• Cosin-Roger J, Simmen S, Melhem H, et al. Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. Nat Commun. 2017;8:98. doi:10.1038/s41467-017-00213-3
   PubMed Web of Science ®Google Scholar
• Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32(3):379–391. doi:10.1016/j.immuni.2010.03.003
   PubMed Web of Science ®Google Scholar
• Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis. 2011;17(6):1359–1372. doi:10.1002/ibd.21478
   PubMed Web of Science ®Google Scholar
• Qu S, Fan L, Qi Y, et al. Akkermansia muciniphila alleviates Dextran Sulfate Sodium (DSS)-induced acute colitis by NLRP3 activation. Microbiol Spectr. 2021;9(2):e0073021. doi:10.1128/Spectrum.00730-21
   PubMed Web of Science ®Google Scholar
• Itani S, Watanabe T, Nadatani Y, et al. NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis. Sci Rep. 2016;6:39075. doi:10.1038/srep39075
   PubMed Web of Science ®Google Scholar
• Funes SC, Rios M, Escobar-Vera J, et al. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186–195. doi:10.1111/imm.12910
   PubMed Web of Science ®Google Scholar
• Orecchioni M, Ghosheh Y, Pramod AB, et al. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS–) vs. alternatively activated macrophages. Front Immunol. 2019;10:1084. doi:10.3389/fimmu.2019.01084
   PubMed Web of Science ®Google Scholar
• Wu MM, Wang QM, Huang BY, et al. Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. 2021;172:105796. doi:10.1016/j.phrs.2021.105796
   PubMed Web of Science ®Google Scholar
• Yan YX, Shao MJ, Qi Q, et al. Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages. Acta Pharmacol Sin. 2018;39(10):1633–1644. doi:10.1038/aps.2017.185
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li X, Chen J, et al. The pentacyclic triterpene lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease. Int Immunopharmacol. 2016;30:74–84. doi:10.1016/j.intimp.2015.11.031
   PubMed Web of Science ®Google Scholar
• Wei -Y-Y, Fan Y-M, Ga Y, et al. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF-kappaB pathway. Phytomedicine. 2021;92:153743. doi:10.1016/j.phymed.2021.153743
   PubMed Web of Science ®Google Scholar
• Zhuang H, Lv Q, Zhong C, et al. Tiliroside ameliorates ulcerative colitis by restoring the M1/M2 macrophage balance via the HIF-1alpha/glycolysis pathway. Front Immunol. 2021;12:649463. doi:10.3389/fimmu.2021.649463
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu X, Wan C, et al. NLRP3 inflammasome mediates M1 macrophage polarization and IL-1beta production in inflammatory root resorption. J Clin Periodontol. 2020;47:451–460. doi:10.1111/jcpe.13258
   PubMed Web of Science ®Google Scholar
• Liu T, Wang L, Liang P, et al. USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy. Cell Mol Immunol. 2021;18(10):2431–2442. doi:10.1038/s41423-020-00567-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Gao X, Miao Y, et al. NLRP3 regulates macrophage M2 polarization through up-regulation of IL-4 in asthma. Biochem J. 2018;475(12):1995–2008. doi:10.1042/BCJ20180086
   PubMed Web of Science ®Google Scholar
• Ye Y, Jin T, Zhang X, et al. Meisoindigo protects against focal cerebral ischemia-reperfusion injury by inhibiting NLRP3 inflammasome activation and regulating microglia/macrophage polarization via TLR4/NF-kappaB signaling pathway. Front Cell Neurosci. 2019;13:553. doi:10.3389/fncel.2019.00553
   PubMed Web of Science ®Google Scholar
• Wu K, Yuan Y, Yu H, et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood. 2020;136(4):501–515. doi:10.1182/blood.2019003990
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhou H, Bu Q, et al. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. J Hepatol. 2022;77(2):312–325. doi:10.1016/j.jhep.2022.02.031
   PubMed Web of Science ®Google Scholar
• Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14(5):269–278. doi:10.1038/nrgastro.2016.208
   PubMed Web of Science ®Google Scholar